


I hereby certify that this correspondence is being electronically filed in the United States Patent and Trademark Office on November 19, 2007.



Frank C. Eisenschenk, Ph.D., Patent Attorney

ELECTION UNDER 35 U.S.C. § 121
Examining Group 1649
Patent Application
Docket No. ARS-117
Serial No. 10/550,775

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Stacey Nee MacFarlane
Art Unit : 1649
Applicants : Georg Feger, Ursula Boschert, Yves Sagot, Ruben Papoian
Serial No. : 10/550,775
Filed : September 27, 2005
Conf. No. : 1797
For : Use of Clusterin for the Treatment and/or Prevention of Peripheral Neurological Diseases

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313


ELECTION UNDER 35 U.S.C. § 121

Sir:

In response to the written Restriction Requirement dated October 18, 2007 in the above-identified patent application, Applicants hereby elect to prosecute the invention of Group I (claims 26-39) without traverse. As the species, Applicants hereby elect traumatic nerve injury of the peripheral nervous system (PNS). Claims 26, 27 and 32-39 read on the elected invention.

The Commissioner is hereby authorized to charge any fees under 37 CFR §§1.16 or 1.17 as required by this paper to Deposit Account No. 190065.

Respectfully submitted,



Frank C. Eisenschenk, Ph.D.
Patent Attorney
Registration No. 45,332
Phone No.: 352-375-8100
Fax No.: 352-372-5800
Address: P.O. Box 142950
Gainesville, FL 32614-2950

FCE/mnl